Literature DB >> 25965986

[Economic burden of Clostridium difficile enterocolitis in German hospitals based on routine DRG data].

R F Grube1, W Heinlein1, H Scheffer1, M Rathmayer1, W Schepp2, A W Lohse3, A Stallmach4, M H Wilke, M M Lerch.   

Abstract

BACKGROUND: Clostridium difficile associated diarrhea (CDAD) is not only a increasing medical but also economical problem.
METHODS: Data from the DRG project group of the German society for digestive and metabolic diseases (DGVS) were analyzed for CDAD. Out of 430,875 cases from 37 German hospitals 2,767 cases were grouped by having CDAD either as primary (PD) or secondary diagnosis (SD; likely to be from a hospital source) in an initial or recurring hospital stay (RD). For comparison non-CDAD cases from the same hospitals from that year where matched using propensity score matching. As endpoints we defined LOS (length of stay), difference of LOS to national average LOS, total costs per case and difference between costs and revenue for all three groups.
RESULTS: Patients from the PD group (n = 817) showed a mean LOS of 11.2 days compared to 8.5 days for the control group, 4,132 € mean cost per case (536 € more than control) and a mean loss of -1,064 € per case compared to -636 €. In the SD group (n = 1,840) patients stayed in the hospital for 28.8 days (control: 18.1 days), had costs of 19,381 € (control: 13,082 €) and a loss of -3,442 € compared to -849 € in the control group. Recurring cases (RD; n = 110) showed a LOS of 37.3 days (control: 21.3 days), had even higher costs (20.755 € vs. 13,101 €) and higher losses (-4,196 € vs. -1,109 €).
CONCLUSION: By extrapolating these findings CDAD not only harms patients but generates a yearly cost burden of 464 million € for the German healthcare system including a loss of 197 million € for German hospitals. To the authors' opinion sufficient measures against CDAD should include pre hospital risk reduction programs, introduction of effective therapeutic and hygienic strategies in hospitals as well as improvements in documentation for these cases to support further developments of the German DRG system. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2015        PMID: 25965986     DOI: 10.1055/s-0034-1398803

Source DB:  PubMed          Journal:  Z Gastroenterol        ISSN: 0044-2771            Impact factor:   2.000


  3 in total

Review 1.  Economic burden and cost-effectiveness of therapies for Clostridiodes difficile infection: a narrative review.

Authors:  Akshita Gupta; Ashwin N Ananthakrishnan
Journal:  Therap Adv Gastroenterol       Date:  2021-05-30       Impact factor: 4.409

2.  A cost-effectiveness and budget impact analysis of first-line fidaxomicin for patients with Clostridium difficile infection (CDI) in Germany.

Authors:  Maureen Watt; Charles McCrea; Sukhvinder Johal; John Posnett; Jameel Nazir
Journal:  Infection       Date:  2016-04-09       Impact factor: 3.553

3.  Costs of hospital-acquired Clostridium difficile infections: an analysis on the effect of time-dependent exposures using routine and surveillance data.

Authors:  Thomas Heister; Martin Wolkewitz; Philip Hehn; Jan Wolff; Markus Dettenkofer; Hajo Grundmann; Klaus Kaier
Journal:  Cost Eff Resour Alloc       Date:  2019-08-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.